Form 4: Beta Bionics Chief Medical Officer Acquires Stock Options
SEC Form 4 Filing
Beta Bionics' Chief Medical Officer, Steven Jon Russell, acquired stock options on January 31, 2025, as detailed in a recent SEC Form 4 filing.
Summary
- Steven Jon Russell, Chief Medical Officer of Beta Bionics, acquired employee stock options on January 31, 2025.
- These options are for the right to buy common stock at prices of $7.51, $5.10, and $17.00 per share.
- The options vest over time, with different vesting schedules for each grant.
- The total number of shares underlying these options is 225,438.
- The filing was signed by Stephen Feider, Attorney-in-Fact, on February 3, 2025.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.
Positives
- The acquisition of stock options by a key executive like the Chief Medical Officer can be seen as a positive sign of their commitment to the company's future.
- The vesting schedules of the options align the executive's interests with the long-term performance of the company.
Risks
- The exercise of these options could potentially dilute existing shareholders if the shares are issued from treasury stock.
Industry Context
This filing is a routine disclosure of stock option grants to a company executive, which is common practice in publicly traded companies to incentivize performance and align management interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in the biotechnology industry, similar to companies like Insulet and Dexcom.
- The vesting schedules and exercise prices are typical for such grants, designed to incentivize long-term value creation.
Stakeholder Impact
- Shareholders may view this as a positive sign of management's commitment.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 2022-11-14 | Date from which vesting of some options begins. |
| 2023-09-14 | Date from which vesting of some options begins. |
| 2025-01-29 | Date from which vesting of some options begins. |
| 2025-01-31 | Date of the stock option acquisition. |
| 2025-02-03 | Date the SEC Form 4 was signed. |
| 2032-12-14 | Expiration date of some options. |
| 2033-09-13 | Expiration date of some options. |
| 2035-01-28 | Expiration date of some options. |
Keywords
stock options, SEC Form 4, insider trading, Beta Bionics, executive compensation, Steven Jon Russell, BBNX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.